IP Library › Granted Patent US 9,822,407
Granted Patent B2
US 9,822,407 · App. 15/192,753 · Granted Nov 21, 2017

Genomewide unbiased identification of DSBs evaluated by sequencing (GUIDE-Seq)

Inventors: J. Keith Joung (Winchester, MA); Shengdar Tsai (Charlestown, MA)
Assignee: The General Hospital Corporation
C12Q1/6869C12Q1/6855
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,407
App. No.
15/192,753
Granted
Nov 21, 2017
Kind
B2
Abstract

Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.

Claims (32)

1. A method for detecting double stranded breaks (DSBs) in genomic DNA (gDNA) of a cell, the method comprising:

contacting the cell with a blunt-ended double-stranded oligodeoxynucleotide (dsODN), wherein both strands of the dsODN are orthogonal to the genome of the cell, and further wherein (a) the 5′ ends of the dsODN are phosphorylated, and (b) phosphorothioate linkages are present on both 3′ ends, or phosphorothioate linkages are present on both 3′ ends and both 5′ ends;

expressing or activating an exogenous engineered nuclease in the cell, for a time sufficient for the nuclease to induce DSBs in the genomic DNA of the cell, and for the cell to repair the DSBs, integrating a dsODN at one or more DSBs;

amplifying a portion of genomic DNA comprising an integrated dsODN; and

sequencing the amplified portion of the genomic DNA,

thereby detecting a DSB in the genomic DNA of the cell.

2. The method of claim 1 , wherein amplifying a portion of the genomic DNA comprises:

fragmenting the DNA;

ligating ends of the fragmented genomic DNA from the cell with a universal adapter; and performing polymerase chain reaction (PCR) on the ligated DNA.

3. The method of claim 1 , wherein the engineered nuclease is selected from the group consisting of meganucleases, zinc-finger nucleases, transcription activator effector-like nucleases (TALEN), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas RNA-guided nucleases (CRISPR/Cas RGNs).

4. The method of claim 1 , wherein the DSBs are off-target DSBs.

5. The method of claim 1 , wherein the cell is a mammalian cell.

6. The method of claim 1 , wherein the engineered nuclease is a Cas9 nuclease, and the method also includes expressing in the cells a guide RNA that directs the Cas9 nuclease to a target sequence in the genome.

7. The method of claim 1 , wherein the dsODN is 30-35 nts long.

8. The method of claim 1 , wherein the dsODN is phosphorylated on the 5′ ends, and phosphorothioated on the 3′ ends.

9. The method of claim 1 , wherein the dsODN contains a randomized DNA barcode.

10. The method claim 1 , comprising:

shearing the gDNA into fragments; and

preparing the fragments for sequencing by end-repair, a-tailing, and ligation of a single-tailed sequencing adapter.

11. The method of claim 1 , wherein the dsODN is between 15 and 50 nts long.

12. A method of determining which of a plurality of guide RNAs is most specific, the method comprising:

contacting a first population of cells with a first guide RNA and a blunt-ended double-stranded oligodeoxynucleotide (dsODN), wherein both strands of the dsODN are orthogonal to the genome of the cell, and further wherein (a) the 5′ ends of the dsODN are phosphorylated, and (b) phosphorothioate linkages are present on both 3′ ends, or phosphorothioate linkages are present on both 3′ ends and both 5′ ends;

expressing or activating an exogenous Cas9 engineered nuclease in the first population of cells, for a time sufficient for the nuclease to induce DSBs in the genomic DNA of the cells, and for the cells to repair the DSBs, integrating a dsODN at one or more DSBs;

amplifying a portion of genomic DNA from the first population of cells comprising an integrated dsODN;

sequencing the amplified portion of the genomic DNA from the first population of cells;

determining a number of sites at which the dsODN integrated into the genomic DNA of the first population of cells;

contacting a second population of cells with a second guide RNA and a blunt-ended double-stranded oligodeoxynucleotide (dsODN), wherein both strands of the dsODN are orthogonal to the genome of the cell, and further wherein (a) the 5′ ends of the dsODN are phosphorylated, and (b) phosphorothioate linkages are present on both 3′ ends, or phosphorothioate linkages are present on both 3′ ends and both 5′ ends;

expressing or activating an exogenous Cas9 engineered nuclease in the second population of cells, for a time sufficient for the nuclease to induce DSBs in the genomic DNA of the second population of cells, and for the cells to repair the DSBs, integrating a dsODN at one or more DSBs;

amplifying a portion of genomic DNA comprising an integrated dsODN from the second population of cells;

sequencing the amplified portion of the genomic DNA from the second population of cells;

determining a number of sites at which the dsODN integrated into the genomic DNA of the second population of cells; and

comparing the number of sites at which the dsODN integrated into the genomic DNA of the first population of cells to the number of sites at which the dsODN integrated into the genomic DNA of the second population of cells to determine if the first or second guide RNA is more specific.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2017
From: JOUNG, J. KEITH; TSAI, SHENGDAR
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 042142/0072 →
Continuity (6)
Continuation PCTUS2015037269 · Jun 23, 2015
Provisional Application 62015911 · Jun 23, 2014
Provisional Application 62077844 · Nov 10, 2014
Provisional Application 62078923 · Nov 12, 2014
Provisional Application 62088223 · Dec 5, 2014
Related Publication 20160304950A1 · Oct 20, 2016